Archive for June, 2012
Issuance of Complete Response Letter for Eliquis Doesn’t Alter My Buy on Bristol-Myers Squibb
Investment Opinion I believe that the issuance of a Complete Response Letter to Bristol-Myers Squibb (BMY) and Pfizer (PFE) for the use of Eliquis to prevent stokes caused by atrial fibrillation is a minor setback and believe that the issue can be resolved and the product approved by October at the earliest and April of […]
Cadence (CADX): Ofirmev Sales Could Surprise on the Upside in Second Quarter and Generic Concerns Appear to be Overblown
Cadence (CADX) has just released estimates from the independent market research firm Wolters, Kluwer on the number of vials that were shipped in April and May. The results are encouraging and suggest that Ofirmev could produce an upside sales surprise in upcoming second quarter. Management issued guidance after the first quarter for Ofirmev sales of […]
Cadence Pharmaceuticals: Ofirmev Sales are Likely to Surprise on the Upside in the Second Quarter and Fears of Generic Competition are Overblown (CADX; $2.91)
Investment Summary and Thesis In my report of May 31, 2012, I stated that management guidance for Ofirmev sales of $10.0 to $10.5 million for 2Q, 2012 seemed low and I was using a higher estimate of $10.5 million to $11.1 million. Cadence just released market research data on the number of Ofirmev vials shipped […]
InSite Vision: Initiation of Coverage on Promising Late Stage Ophthalmology Company (INSV, $0.30)
Report Overview The core technology of InSite Vision is its DuraSite delivery system that delivers drugs more effectively to the eye. The continual blinking of the eye can quickly wash out topical formulations and in order to retain effective drug levels in eye tissue, most drugs have to be given four to eight times per […]
InSite Vision: Initiating Coverage on a Promising Company with a Robust Late Stage Product Portfolio
I have just published a new report and initiated coverage of InSite Vision (INSV, $0.30) with a Buy. The core technology of InSite Vision is its DuraSite drug delivery system that delivers drugs more effectively to the eye. The continual blinking of the eye can quickly wash out topical formulations and in order to retain […]